Items where authors include "Elliott, F"

Article

Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736

Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Seligmann, JF, Elliott, F, Richman, S orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2020) Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. Annals of Oncology, 31 (8). pp. 1021-1029. ISSN 0923-7534

Burn, J, Sheth, H, Elliott, F et al. (20 more authors) (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. The Lancet, 395 (10240). pp. 1855-1863. ISSN 0140-6736

Hardie, CM, Elliott, F, Chan, M et al. (3 more authors) (2020) Environmental exposures such as smoking and low vitamin D are predictive of poor outcome in cutaneous melanoma rather than other deprivation measures. Journal of Investigative Dermatology, 140 (2). pp. 327-337. ISSN 0022-202X

Huyghe, JR, Bien, SA, Harrison, TA et al. (196 more authors) (2019) Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 51 (1). pp. 76-87. ISSN 1061-4036

Seligmann, JF, Hatch, AJ, Richman, SD orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2018) Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncology, 4 (4). pp. 564-568. ISSN 2374-2437

Sheth, H, Northwood, E, Ulrich, CM et al. (19 more authors) (2018) Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. PLoS ONE, 13 (2). e0192223. ISSN 1932-6203

Seligmann, JF, Fisher, D, Smith, CG et al. (9 more authors) (2017) Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568. ISSN 0923-7534

O'Shea, SJ orcid.org/0000-0002-1588-6022, Robles-Espinoza, C, McLellan, L et al. (10 more authors) (2017) A population-based analysis of germline BAP1 mutations in melanoma. Human Molecular Genetics, 26 (4). pp. 717-728. ISSN 0964-6906

O'Shea, SJ, Merchant, W, Laye, J et al. (5 more authors) (2017) Transcriptomic profiling the microenvironment in primary melanoma. Pigment Cell and Melanoma Research, 30 (1). p. 127. ISSN 1755-148X

Rogers, Z, Elliott, F, Kasparian, NA et al. (3 more authors) (2016) Psychosocial, clinical and demographic features related to worry in patients with melanoma. Melanoma Research, 26 (5). pp. 497-504. ISSN 0960-8931

Seligmann, JF, Elliott, F, Richman, SD et al. (7 more authors) (2016) Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA oncology, 2 (5). pp. 633-642. ISSN 2374-2437

Abbotts, R, Jewell, R, Nsengimana, J et al. (13 more authors) (2014) Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget, 5 (10). pp. 3273-3286. ISSN 1949-2553

Teo, MTW, Landi, D, Taylor, CF et al. (7 more authors) (2012) The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis, 33 (3). pp. 581-586. ISSN 0143-3334

Qiao, BL, Ansari, AH, Scott, GB orcid.org/0000-0003-0021-9400 et al. (11 more authors) (2011) In vitro functional effects of XPC gene rare variants from bladder cancer patients. Carcinogenesis, 32 (4). pp. 516-521. ISSN 0143-3334

Mitra, A, Conway, C, Walker, C et al. (17 more authors) (2010) Melanoma sentinel node biopsy and prediction models for relapse and overall survival. British Journal of Cancer, 103 (8). pp. 1229-1236. ISSN 0007-0920

Conference or Workshop Item

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Proceedings Paper

Seligmann, J, Wood, H orcid.org/0000-0003-3009-5904, Richman, S orcid.org/0000-0003-3993-5041 et al. (6 more authors) (2017) 545P Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Annals of Oncology. 42nd ESMO Congress (ESMO 2017), 08-12 Sep 2017, Madrid, Spain. Oxford University Press , p. 185.

Seligmann, JF, Fisher, D, Smith, CG et al. (8 more authors) (2016) Exploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 03-07 Jun 2016, Chicago, Il. American Society of Clinical Oncology .

Laurent-Puig, P, Paget-Bailly, S, Vernerey, D et al. (12 more authors) (2015) Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial. In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Seligmann, JF, Fisher, D, Elliott, F et al. (8 more authors) (2015) Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .

Seligmann, JF, Elliott, F, Jacobs, B et al. (10 more authors) (2015) HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .